[ad_1]
Los Angeles, California, December 20, 2021 (Global News Agency) – Immix Biopharma, Inc. (NASDAQ:IMMX) (“ImmixBio” or “Company”), a biopharmaceutical company pioneering Tissue Specific Therapy (TSTx)TM value In response to oncology and immune disorders, today announced the completion of an initial public offering of 4,200,000 common shares at a public offering price of US$5.00 per share, with a total proceeds of US$21,000,000, deducting underwriting discounts, commissions and issuance fees. In addition, the company has granted the underwriters a 45-day option to purchase up to 630,000 ordinary shares at the initial public offering price minus the underwriting discount to make up for the over-allotment.
The stock will begin trading on the Nasdaq Capital Market on December 16, 2021, under the ticker symbol “IMMX”.
ThinkEquity served as the sole bookrunner for this issue.
The company intends to use the net proceeds from this issuance to fund the planned IMX-110 phase 2a soft tissue sarcoma clinical trial and IMX-110 + tislelizumab phase 1b combined trial for the IND study of IMX-111 (colorectal cancer) And IMX-120 (Inflammatory Bowel Disease), as well as for working capital and other general corporate purposes.
The registration statement on Form S-1 (Document No. 333-259591) related to stocks has been submitted to the U.S. Securities and Exchange Commission (“SEC”) and will become effective on December 15, 2021. This issuance is only conducted through the prospectus in the following way. A copy of the final prospectus is available on the website of the US Securities and Exchange Commission,
The full story can be found on Benzinga.com
[ad_2]
Source link
